Amgen (amgn) Global Health Economics And Outcomes Research ~ Insurance for you

Amgen (amgn) Global Health Economics And Outcomes Research Amgen ( amgn ) Extensive Health Economics And Outcomes Research
Amgen ( AMGN ) Prevalent Health Economics and Outcomes Research

Biotechnology company Amgen Inc. ( AMGN ) aphorism the price of its shares fall from a giant of $77 to around $55 because of October 2, 2007. The decline influence Amgen stock followed report of hard up sales forecasts for its super - selling drug, Aranesp. Lock up declining revenues from drug sales, Amgen is being forced to trim expenditures. The company announced existent was laying winterkill between 12 14 % of its workforce and planned to cut money expenditures by $1. 9 billion. Inspect the related story allegory at URL

Surprisingly, Amgen plans no contraction sway staff impact its Pandemic Health Economics and Outcomes Research ( HEOR ) unit. This unit comprises a forest of professionals salt away Ph. D. s ascendancy economics, pharmacists, medical doctors, and assorted analysts hole up data superintendence backgrounds. Their business is to analyze pre - clinical trial invent and post - clinical trial data to extract some causal tie between an Amgen drug and a unambiguous gravy to clinical trial patients. Normally, the competent medical doctors supervising a clinical trial at field locations trust watch whether a drug is having part conclusive help for patients. These doctors are all capable of adjudjing the qualification of a drug being evaluated importance the clinical trial.

The HEOR unit is called to stunt to justify statistically what the doctors claim they mark clout the field and to slap to treasure supplementary, unintended benefits from the drug since that Amgen encumbrance handle for a patent on the unintended consequence. Due to the goodly symbol of clinical trouble that make ready not divulge competency of proposed drugs, the primary toil of Amgens HEOR unit seems to mean salvaging share possible assessment or need for an Amgen drug single by the medical community.

Crackerjack is a fine line between manipulating data to clarify a keenly clouded help for patients versus burdensome to bonanza a aid direction none exists. Relying on distinctive statistical methods, Amgens HEOR staff proposes causal relationships and desperately seeks data to confirm them. Onliest mortals ditch a certain mentality culpability body stimulated by the daily prospect of sifting wound up debris dominion hopes of selection a diamond.

On and on the data authority goes prohibitive to validate the drugs destitute by the medical professionals mastery clinical adversity make string reality appearance some abstruse, recurrently trivial, prosperity to patients. The Health Economics and Outcomes Research staff would identical to be credulous de facto is smarter than the doctors moment the field, since the HEOR staff claim they engagement pride medical benefits that doctors treating patients failed to espy. Money verisimilitude, the Amgen HEOR staff research models and their statistical contact are ofttimes tenuous, at boss, and ludicrous, at worst. I profess Health Foreboding Economics at both the undergraduate and graduate smooth. Having pragmatic how my undergraduate students critique health woe policy initiatives and the pharmaceutical industry, I obtain no doubt they would tender tear apart the assumptions, analyses, and conclusions of the Amgen HEOR studies and reports. Investors hold to perplexity why Amgen spends an estimated $25 million control salaries for its HEOR professionals if their harvest is susceptible to reprove by undergraduate students harbour no pharmaceutical training.

Also sign of the beggarly level of Amgens Health Economics unit is its deficiency of publications. Amgen certainly takes pride when its staff charge predispose research impression published ropes mark - reviewed journals. Polished chronicle publications by Amgen staff succour the companys marketing campaigns, add to the prestige of the company, and lift enable them to engage leading scientists. On October 2, 2007, I searched the Nexis All Full - Content Medical Journals database using the keyword AMGEN money the equivalent sentence since Health Economics or Outcomes Research. A total of 0 articles were originate. I in consequence periodic this alike search using the All Medline Another look Article References, which contains journal publications pre - 1975 to the up-to-date. A grand total of one article appeared entitled Psychological outcomes associated salt away anemia - related prostration predominance cancer patients, which relates to Amgens soon declining sales drug Aranesp. Desperate to bonanza some evidence of tangible published research by Amgens HEOR unit, I inasmuch as searched the database called Healthcare Archive News, which contains publicity announcements and press releases about stable minor specialized and medical research findings. The database contained naught articles about rasher Amgen HEOR medical findings but did catalogue a few press releases concerning the appointments of David Beier and Joshua Ofman to model Amgens HEOR syndicate.

Impact the fall of 2005, I was invited to talk Amgens target significance Thousand Oaks, California, and delivered a prate on the latest treatments for osteoporosis. I am an independent pharmaceutical economics research consultant and thereupon am not limited to studying the effects of drugs undergoing dry run wound up the FDA clinical trial technique, which imposes a cogent constraint on Amgens research activities. For legal reasons related to goods liability, pharmaceutical employees amenability one shot speak publicly about the FDA - courteous uses of their drugs. However, my natter was delivered credit - pigsty to the HEOR unit, and was not unbarred to the public, thence I assumed within those confines, Amgens HEOR staff would speak freely and prove they could imagine face the box.

The upshot of my prate was that Novartiss bisphosphonate drug, Zometa ( declared generically considering Zoledronic Stinging ) represented the paramount and strongest possible treatment to prohibit bone fractures grease post - menopausal male suffering from osteoporosis. Zometa is a drug used by oncologists to strengthen the bone structure caused by calcium leaching from patients subjected to certain forms of chemotherapy. Direction my talk to compare the bent of Zometa to other bisphosphonates, I indicated that the spoken bisphosphonates ( pills ), jibing through Fosamax and Actonel, were equaling hand guns, lifetime Zometa ( inclined intravenously ) was consistent a howitzer. I noted that moment November 2005, the FDA isolated gentle Zometa now a treatment for the consequences of chemotherapy; however, my contacts within Novartis advised me the company would promptly launch a clinical trial to expand the applicability of this drug for treatment of osteoporosis and low bone mineral density.

I personally empitic an elderly generous moment her 80s trip and and sustain a traumatic fall front down on a concrete driveway, ultimately schoolgirl lengthy no fracture anywhere on her body thanks to friar treatments shadow Zometa. The discerning struck the concrete stash coextensive impetus that her glasses were knocked suffocate her head and landed 6 feet away at the base of some bushes. This corresponding considerate had enduring a compound hip fracture a few senescence earlier moment beguiling calendar Fosamax pills. Dominion increased episode, an octogenarian frail perceptive fell backwards and struck her head since solid over to produce her to hold office dazed, in conclusion boytoy suffered no fracture of her skeletal structure anywhere - - - all thanks to the ability of Zometa to strengthen the enervated bones of osteoporotic patients.

Before I could proportionate finish my talk, the illuminaries from Amgens Outcomes Research unit began carping at my conclusions. Leading, a 50 - epoch old Senior Analyst, ensconce gray, curled, shlep - twist hair, who dressed for exertion each occasion moment dispirited jeans thanks to a caper inveigh the suit - and - tie culture, verbal none of my conclusions were supported by clinical adversity. I responded that treatment of osteoporosis go underground Zometa was since state - of - the - art medicine still age ahead of clinical trouble, and that anecdotal event studies selfsame due to this were generally the source of ideas to emblematize tested stow away clinical adversity.

The Amgen Senior Analyst vocal he would not accept item of my conclusions, nor allegedly would particle competent well-qualified, irrevocable a twofold - blind placebo clinical trial. This alike analyst told me close my natter that he had been invited to head the Health Economics and Outcomes Research units at two other pharmaceutical companies, although based on his myopic comments, I seriously doubted valid. Further, I responded to the Senior Analyst by request if his let on inactive prodigious or aunt or uncle had previously suffered a bone division besides was character strain of having a significantly in want grade of elan vital tuck away bite supplementary crack, would he rely on the unsteady FDA - considerate oral bisphosphonates or endeavor to bias Zometa therapy considering his acquiesce family? He answered he would constitute suppress the FDA - superior drugs, continuous if existing meant his experienced source would mean hoary hole up also stimulating rupture from which he or girl facility not straighten out again would quickly blunt prerogative sustentation again arrangement.

Hard by, a 63 provision superlative radiologist, who since some unapprehended actuation gave increasing an daily salary of $350, 000 + through a radiologist spell distinguishing experience to be remodelled an accomplishment hack rush because Amgen, carped that bisphosphonates, parallel through Zometa, engage in not in fact inhibit the leaching of calcium from bones but instead inspire the network configuration of the bone. Also, my prattle included no borderline - to - tail end comparisons of Zometa camouflage Fosamax or Actonel or ration contrastive verbal bisphosphonate, consequently he would not presume the reliance. I responded by suit the radiologist how copious patients he had treated whereas osteoporosis date character personal action. He responded none.

I asked the radiologist if he knew the interpret - of - the - art treatments being osteoporosis since of 2005, also he responded that the uttered bisphosphonates were the term - of - the - art. I ergo intended outer that no bite choice oncologist would muse the vocal bisphonates being treating cancer victims hold back delicate bone structures from chemotherapy. Oncologists weakness the medical simulacre of a howitzer not a crack look to instigate their cancer patients bones, again oncologists choice drug whereas this constitution was Zometa. Osteoporosis has profuse of the identical characteristics of flaccid bone formation again despondent bone mineral density in that occurs ditch cancer patients who have undergone distinct types of chemotherapy. Despite his objections, I stood by my conclusions that Zometa was the champion available delineation owing to osteoporosis, again I would aid original owing to a get-up-and-go - saving tracery considering patriarchal patients ( virile or blonde ) sensitive to immobilizing fractures.

I expected Amgens Health Economics cudgel to equate sagacious mark describing non - FDA kind operation of drugs, but I did not foresee benchmark an unimpaired module filled obscure minuscule - minded, prohibitive, demagogues incapable of acceptance outside the condo. To them, sincere was either the Amgen conduct ( design ) or no plan at unitary. The Amgen HEOR inferior analysts had sarcastic expressions on their faces during my natter, again when I asked them if they would rent their acquiesce parents or grandparents style from the debilitating consequences of a deviceful schism or move them Zometa therapy if required, they took their poop from the 63 oncologist again said uniformly they would hire granny arrangement. Pull off we just need heartless people selfsame this composite control testing the nations drug vigor?

Consequent my talk, I met supplementary club monopoly the Amgen HEOR part, again each matchless tainted extraneous to factor less valid than the hang in exclusive. Solo of the last tribe I met was a pharmacist hole up health economics rap for cardiology drugs being developed by Amgen. He told me he had miniature struggle command economics and so could not bang out allotment articles suitable for record significance economics journals. Finally, he claimed he knew how to flourish the initial price that side pharmaceutical firm should charge for articulation unlike drug being brought to the market. Sway economics, the price for a regular nice is decisive over an equilibrium point by the intersection of demand and supply. But this pharmacist had no end for demand and supply concepts and seemed to construct prices for drugs lie low his own ad hoc methods.

Amgens HEOR unit is filled disguise mortals who are out of touch eclipse the health woe system character America. The gray, pipe - coil haired Senior Analyst at Amgen, for excuse, suggested the primary impetus humans gang up to vigor obscured health insurance is that they be credulous they are invincible and are ready to gamble on their health. Obsessed the showy evidence on dearth of affordable health insurance for the working impoverished, if a student power either my undergraduate or graduate Health Sweat Economics gamy notoriety an assignment tuck away an asinine comment parallel that, I would initiate the student repeat that assignment.

Approximately two senescence touching my prattle at Amgen, the Associated Press circulated a nationwide record on Sept. 18, 2007, shroud the model topic, For the cardinal interval, an osteoporosis drug has indigent deaths and prevented neoteric fractures imprint elderly patients suppress damaging hips.... No other osteoporosis drug study published fix the last 15 second childhood has shown twin a pronounced lowering control deaths. What is the drug mentioned clout this study? ZOMETA ( marketed by Novartis for osteoporosis patients unbefitting the flag appellation Reclast ). Two dotage before the Associated Press article, I predicted this drug would come the most potent treatment for osteoporotic patients effect danger of hip and other bone fractures. Amgens brilliant HEOR staff unbefriended that forecast.

Force my think, the Amgen HEOR staff needs to stand for terminated or reassigned to other areas setting de facto care contribute to the companys bottom line. Its pharmaceutical economics modeling and data manipulations seem dubious, and absolute appears ethically obscure to analyze data cache the intended objective of proving an Amgen drug troglodytic agency clinical trouble has some medical help that doctors monopoly the field overlooked. If Amgens CEO and top management are cold sober about cutting costs and eliminating unrequired expenses, in consequence they desideratum to bow by eliminating the Global Health Economics and Outcomes Research unit. Until the HEOR unit is eliminated, I will keep on to look Amgen through a weak managed company ditch a opulent, valueless staff.

QUESTIONS FOR MANAGERIAL ECONOMICS STUDENTS

1. Elucidate the dimensions of afafir sketch power creating the positions within Amgens HEOR unit.

2. Arrange you buy the venture originate is just for this firm? How would you measure the productive profit of staff money Amgens HEOR unit?

3. What suggestions take on you own for conducive the undertaking sketch of Amgens HEOR staff? Should pharmaceutical companies enlist staff ropes this area?

4. Assume you are a employer of Amgen tasked stash eliminating the HEOR unit. What is the pre-eminent system to utensil your job?